One Cavendish Place
4th Floor
London W1G 0QF
United Kingdom
44 33 3023 7300
https://www.mereobiopharma.com
Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 33
Name | Title | Pay | Exercised | Year born |
---|---|---|---|---|
Dr. Denise Vera Scots-Knight Ph.D. | Co-Founder, CEO & Executive Director | 890.56k | N/A | 1959 |
Mr. Charles Edward Sermon | Co-Founder, General Counsel, Business Development & Company Secretary | 625.79k | N/A | 1969 |
Ms. Christine Fox CPA | Chief Financial Officer | 569.77k | N/A | 1981 |
Dr. John P. Richard M.B.A. | Co-Founder & Chief Business Officer | N/A | N/A | 1957 |
Dr. John A. Lewicki Ph.D. | Chief Scientific Officer | N/A | N/A | 1952 |
Dr. Jackie Parkin | Senior VP & Therapeutic Head | N/A | N/A | 1958 |
Ms. Alexandra Hughes-Wilson | Chief of Patient Access & Commercial Planning | N/A | N/A | 1971 |
Dr. Suba Krishnan | Senior Vice President of Clinical Development | N/A | N/A | 1965 |
Mr. Bo Kara | Senior VP and Head of Pharmaceutical Development & CMC | N/A | N/A | N/A |
Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally. It develops Etigilimab (MPH-313), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumors. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism which is in Phase 2 trials. In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), an antibody for the treatment of osteogenesis imperfecta; and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 anti-trypsin deficiency. The company has a license agreement with Feng Biosciences for the development and commercialization of navicixizumab; license agreement with ReproNovo for the development and commercialization of leflutrozole; licensing agreement with AstraZeneca; and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize setrusumab. Mereo BioPharma Group plc was incorporated in 2015 and is headquartered in London, the United Kingdom.
Mereo BioPharma Group plc’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.